tetano
Editor, Senior Moderator
Ann Lab Med
. 2021 Nov 1;41(6):577-587.
doi: 10.3343/alm.2021.41.6.577.
Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays
Sojeong Yun[SUP] 1 [/SUP], Ji Hyeong Ryu[SUP] 2 [/SUP], Joo Hee Jang[SUP] 1 [/SUP], Hyunjoo Bae[SUP] 1 [/SUP], Seung-Hyo Yoo[SUP] 2 [/SUP], Ae-Ran Choi[SUP] 2 [/SUP], Sung Jin Jo[SUP] 3 [/SUP], Jihyang Lim[SUP] 3 [/SUP], Jehoon Lee[SUP] 3 [/SUP], Hyejin Ryu[SUP] 4 [/SUP], Sung-Yeon Cho[SUP] 5 6 [/SUP], Dong-Gun Lee[SUP] 5 6 [/SUP], Jongmin Lee[SUP] 7 [/SUP], Seok Chan Kim[SUP] 7 [/SUP], Yeon-Joon Park[SUP] 2 [/SUP], Hyeyoung Lee[SUP] 8 [/SUP], Eun-Jee Oh[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays have high clinical utility in managing the pandemic. We compared antibody responses and seroconversion of coronavirus disease 2019 (COVID-19) patients using different immunoassays.
Methods: We evaluated 12 commercial immunoassays, including three automated chemiluminescent immunoassays (Abbott, Roche, and Siemens), three enzyme immunoassays (Bio-Rad, Euroimmun, and Vircell), five lateral flow immunoassays (Boditech Med, SD biosensor, PCL, Sugentech, and Rapigen), and one surrogate neutralizing antibody assay (GenScript) in sequential samples from 49 COVID-19 patients and 10 seroconversion panels.
Results: The positive percent agreement (PPA) of assays for a COVID-19 diagnosis ranged from 84.0% to 98.5% for all samples (>14 days after symptom onset), with IgM or IgA assays showing higher PPAs. Seroconversion responses varied across the assay type and disease severity. Assays targeting the spike or receptor-binding domain protein showed a tendency for early seroconversion detection and higher index values in patients with severe disease. Index values from SARS-CoV-2 binding antibody assays (three automated assays, one LFIA, and three EIAs) showed moderate to strong correlations with the neutralizing antibody percentage (r=0.517-0.874), and stronger correlations in patients with severe disease and in assays targeting spike protein. Agreement among the 12 assays was good (74.3%-96.4%) for detecting IgG or total antibodies.
Conclusions: Positivity rates and seroconversion of SARS-CoV-2 antibodies vary depending on the assay kits, disease severity, and antigen target. This study contributes to a better understanding of antibody response in symptomatic COVID-19 patients using currently available assays.
Keywords: Correlation; Disease severity; Immunoassays; Neutralizing antibody; Positive percent agreement; SARS-CoV-2 antibody; Seroconversion.
. 2021 Nov 1;41(6):577-587.
doi: 10.3343/alm.2021.41.6.577.
Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays
Sojeong Yun[SUP] 1 [/SUP], Ji Hyeong Ryu[SUP] 2 [/SUP], Joo Hee Jang[SUP] 1 [/SUP], Hyunjoo Bae[SUP] 1 [/SUP], Seung-Hyo Yoo[SUP] 2 [/SUP], Ae-Ran Choi[SUP] 2 [/SUP], Sung Jin Jo[SUP] 3 [/SUP], Jihyang Lim[SUP] 3 [/SUP], Jehoon Lee[SUP] 3 [/SUP], Hyejin Ryu[SUP] 4 [/SUP], Sung-Yeon Cho[SUP] 5 6 [/SUP], Dong-Gun Lee[SUP] 5 6 [/SUP], Jongmin Lee[SUP] 7 [/SUP], Seok Chan Kim[SUP] 7 [/SUP], Yeon-Joon Park[SUP] 2 [/SUP], Hyeyoung Lee[SUP] 8 [/SUP], Eun-Jee Oh[SUP] 2 [/SUP]
Affiliations
- PMID: 34108285
- DOI: 10.3343/alm.2021.41.6.577
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays have high clinical utility in managing the pandemic. We compared antibody responses and seroconversion of coronavirus disease 2019 (COVID-19) patients using different immunoassays.
Methods: We evaluated 12 commercial immunoassays, including three automated chemiluminescent immunoassays (Abbott, Roche, and Siemens), three enzyme immunoassays (Bio-Rad, Euroimmun, and Vircell), five lateral flow immunoassays (Boditech Med, SD biosensor, PCL, Sugentech, and Rapigen), and one surrogate neutralizing antibody assay (GenScript) in sequential samples from 49 COVID-19 patients and 10 seroconversion panels.
Results: The positive percent agreement (PPA) of assays for a COVID-19 diagnosis ranged from 84.0% to 98.5% for all samples (>14 days after symptom onset), with IgM or IgA assays showing higher PPAs. Seroconversion responses varied across the assay type and disease severity. Assays targeting the spike or receptor-binding domain protein showed a tendency for early seroconversion detection and higher index values in patients with severe disease. Index values from SARS-CoV-2 binding antibody assays (three automated assays, one LFIA, and three EIAs) showed moderate to strong correlations with the neutralizing antibody percentage (r=0.517-0.874), and stronger correlations in patients with severe disease and in assays targeting spike protein. Agreement among the 12 assays was good (74.3%-96.4%) for detecting IgG or total antibodies.
Conclusions: Positivity rates and seroconversion of SARS-CoV-2 antibodies vary depending on the assay kits, disease severity, and antigen target. This study contributes to a better understanding of antibody response in symptomatic COVID-19 patients using currently available assays.
Keywords: Correlation; Disease severity; Immunoassays; Neutralizing antibody; Positive percent agreement; SARS-CoV-2 antibody; Seroconversion.